Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine

Vaccine

Volumn 27, Issue 33, 2009, Pages 4408-4411

  Sakou, Irine Ikbale ^a,b   Tzanakaki, Georgina ^a   Tsolia, Maria N ^b   Sioumala, Maria ^a   Barbouni, Anastasia ^a   Kyprianou, Miltiades ^a   Papaevangelou, Vana ^b   Tsitsika, Artemis ^b   Blackwell, Caroline C ^a,c   Kafetzis, Dimitris ^b   Kremastinou, Jenny ^a  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Adolescence; Bactericidal activity; Children; MenC vaccine

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MENINGOCOCCUS VACCINE;

ADOLESCENCE; ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; CHILDHOOD; CONTROLLED STUDY; FEMALE; GEOMETRY; HUMAN; IMMUNIZATION; INFANCY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SERUM BACTERICIDAL ACTIVITY; SINGLE DRUG DOSE; VACCINATION;

ADOLESCENT; AGE FACTORS; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; GREECE; HUMANS; IMMUNOGLOBULIN G; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; TIME FACTORS; VACCINES, CONJUGATE;

EID: 67649491062     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.047     Document Type: Article

References (20)

1. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., and Hughes J.M. Meningococcal disease. N Engl J Med 344 18 (2001) 1378-1388
2. Miller E., Salisbury D., and Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 Suppl. 1 (2001) S58-S67
3. Kafetzis D.A., Stamboulidis K.N., Tzanakaki G., Kourea Kremastinou J., Skevaki C.L., Konstantopoulos A., et al. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians. Clin Microbiol Infect 13 5 (2007) 550-552
4. Georgakopoulou T., Danis K., Menegas D., Dedoukou X., Hliodromiti Z., Kavaka N., et al. National vaccine survey 2006: evaluation of the vaccine coverage in teenagers 7th National Congress in Public Health (abstract no. 73). Athens, February (2008) 128
5. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., and Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364 (2004) 365-367
6. Richmond P., Borrow R., Miller E., Clark S., Sadler F., Fox A., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 179 6 (1999) 1569-1572
7. Snape M.D., Kelly D.F., Green B., Moxon E.R., Borrow R., and Pollard A.J. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. J Ped Infect Dis 24 2 (2005) 128-131
8. Snape M.D., Kelly D.F., Salt P., Green S., Snowden C., Diggle L., et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 43 11 (2006) 1387-1394
9. Snape M.D., Kelly D.F., Lewis S., Banner C., Kibwana L., Moore C.E., et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 336 (2008) 1487-1491
10. Kremastinou J., Tzanakaki G., Kansouzidou A., Pagalis A., Danielides V., Kouppari G., et al. Recent emergence of serogroup C meningococcal disease in Greece. FEMS Immunol Med Microbiol 23 1 (1999) 49-55
11. Borrow R., Andrews N., Goldblatt D., and Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: re-evaluation of correlates of protection. Infect Immun 69 3 (2001) 1568-1573
12. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from posst
13. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immun 4 2 (1997) 156-167
14. Gheesling L.L., Carlone G.M., Pais L.B., Holder P.F., Maslanka S.E., Plikaytis B.D., et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol 32 6 (1994) 1475-1482
15. MacLennan J.M., Shackley F., Heath P.T., Deeks J.J., Flamank C., Herbert M., et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 283 21 (2000) 2795-2801
16. Chief Medical Officer. Planned changes to the routine immunization schedule. Department of Health, 8-2-2006. Available from http://www.dh.gov.uk/assetRoot/04/12/81/21/04128121.pdf (accessed 02.09.08).
17. Trotter C.L., Borrow R., Findlow J., Holland A., Frankland S., Andrews N.J., et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol 15 11 (2008) 1694-1698
18. Kremastinou J., Tzanakaki G., Levidiotou S., Markou F., Themeli E., Voyiatzi A., et al. Carriage of Neisseria meningitidis and Neisseria lactamica in northern Greece. FEMS Immunol Med Microbiol 39 (2003) 23-29
19. Ramsay M.E., Andrews N., Kaczmarski E.B., and Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357 (2001) 195-196
20. Maiden M.C., Ibarz-Pavon A.B., Urwin R., Gray S.J., Andrews N.J., Clarke S.C., et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 197 (2008) 737-743